Africare, Washington, DC.
Department of Epidemiology and Social Medicine, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):605-611. doi: 10.1097/QAI.0000000000001862.
The World Health Organization recommends integrating services for patients coinfected with tuberculosis (TB) and HIV. We assessed the effect of TB/HIV integration on antiretroviral therapy (ART) initiation and TB treatment outcomes among TB/HIV-coinfected patients using data collected from 14 rural health facilities during 2 previous TB and HIV quality of care studies.
A facility was considered to have integrated TB/HIV services if patients with TB/HIV had combined treatment for both illnesses by 1 provider or care team at 1 treatment location. We analyzed the effect of integration by conducting a cross-sectional analysis of integrated and nonintegrated facility periods comparing performance on ART initiation and TB treatment outcomes. We conducted logistic regression, with the patient as the unit of analysis, controlling for other intervention effects, adjusting for age and sex, and clustering by health facility.
From January 2012 to June 2014, 996 patients with TB were registered, 97% were tested for HIV, and 404 (42%) were HIV-positive. Excluding transfers, 296 patients were eligible for analysis with 117 and 179 from nonintegrated and integrated periods, respectively. Being treated in a facility with TB/HIV integration was associated with lower mortality [adjusted odds ratio (aOR) = 0.38, 95% confidence interval (CI): 0.18 to 0.77], but there was no difference in the proportion initiating ART (aOR = 1.34, 95% CI: 0.40 to 4.47), with TB treatment success (aOR = 1.43, 95% CI: 0.73 to 2.82), lost to follow-up (aOR = 1.64, 95% CI: 0.53 to 5.04), or failure (aOR = 1.21, 95% CI: 0.34 to 4.32).
TB/HIV service integration was associated with lower mortality during TB treatment even in settings with suboptimal proportions of patients completing TB treatment and starting on ART.
世界卫生组织建议为同时感染结核病(TB)和艾滋病毒的患者整合服务。我们使用从之前的两项结核病和艾滋病毒护理质量研究中从 14 个农村卫生机构收集的数据评估了 TB/HIV 整合对合并感染 TB/HIV 患者开始抗逆转录病毒治疗(ART)和结核病治疗结局的影响。
如果 TB/HIV 患者由 1 名提供者或护理团队在 1 个治疗地点同时治疗这两种疾病,则认为该机构提供了 TB/HIV 整合服务。我们通过对整合和非整合设施时期进行横断面分析,比较 ART 启动和结核病治疗结局方面的表现,来分析整合的效果。我们进行了逻辑回归分析,以患者为单位进行分析,控制了其他干预效果,调整了年龄和性别,并按卫生机构进行了聚类。
从 2012 年 1 月至 2014 年 6 月,登记了 996 例结核病患者,97%接受了艾滋病毒检测,其中 404 例(42%)艾滋病毒阳性。不包括转院患者,有 296 例符合分析条件,分别来自非整合期和整合期的 117 例和 179 例。在提供 TB/HIV 整合服务的机构中,死亡率较低[调整后的优势比(aOR)=0.38,95%置信区间(CI):0.18 至 0.77],但开始接受 ART 的比例没有差异[aOR=1.34,95%置信区间(CI):0.40 至 4.47],结核病治疗成功率[aOR=1.43,95%置信区间(CI):0.73 至 2.82]、失访[aOR=1.64,95%置信区间(CI):0.53 至 5.04]或失败[aOR=1.21,95%置信区间(CI):0.34 至 4.32]。
即使在结核病治疗完成率和开始接受 ART 治疗率不理想的情况下,TB/HIV 服务整合也与结核病治疗期间的死亡率降低相关。